5

BAY-850

5 Cited Publications

Cat. No.: HY-119254

CAS No.: 2099142-76-2

Purity: 98.33%

Target:

Epigenetic Reader Domain

Research Areas:

Metabolic Disease

BAY-850, a chemical probe, is a potent and isoform selective ATPase family AAA domain-containing protein 2 (ATAD2) inhibitor, with an IC₅₀ of 166 nM .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

KL201

2 Cited Publications

Cat. No.: HY-134194

CAS No.: 302939-48-6

Purity: 98.18%

Target:

Cryptochrome

Research Areas:

Metabolic Disease

KL201 a circadian clock modulator, is a isoform-selective cryptochrome 1 (CRY1) stabilizer. KL201 has no stabilizing effect on CRY2. KL201 lengthens the period of circadian rhythms in cells and tissues .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

2

Coumberone

2 Cited Publications

Cat. No.: HY-D1341

CAS No.: 878019-47-7

Research Areas:

Cancer

Coumberone is a metabolic fluorogenic probe, and isoform-selective substrate for all AKR1C isoforms. Coumberone can be reduced by all four members of the AKR1C family to its fluorescent alcohol coumberol. Coumberone can be used for the research of AKR1C .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

KT109

1 Cited Publications

Cat. No.: HY-18540

CAS No.: 1402612-55-8

Target:

MAGL DAGL

Research Areas:

Metabolic Disease Inflammation/Immunology

KT109 is a potent and an isoform-selective inhibitor of diacylglycerol lipase-β (DAGLβ) with an IC₅₀ of 42 nM. KT109 has ~60-fold selectivity for DAGLβ over DAGLα. KT109 shows inhibitory activity against PLA2G7 (IC₅₀=1 µM). KT109 shows negligible activity against FAAH, MGLL, ABHD11, and cytosolic phospholipase A2 (cPLA2 or PLA2G4A). KT109 perturbs a lipid network involved in macrophage inflammatory responses and lowers 2-Arachidonoylglycerol (HY-W011051), Arachidonic acid (HY-109590) and eicosanoids in mouse peritoneal macrophages .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

AS-604850

1 Cited Publications

Cat. No.: HY-13531

CAS No.: 648449-76-7

Purity: 99.95%

Target:

PI3K

Research Areas:

Cancer

AS-604850 is a potent, selective and ATP-competitive PI3Kγ inhibitor with an IC₅₀ value of 0.25 μM and a K_i value of 0.18 μM. AS-604850 shows isoform selective inhibitor of PI3Kγ with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

AC-55649

1 Cited Publications

Cat. No.: HY-108526

CAS No.: 59662-49-6

Purity: 99.70%

Target:

RAR/RXR Autophagy

Research Areas:

Others

AC-55649 is a potent, highly isoform-selective agonist of human RARβ2 receptor, with a pEC₅₀ of 6.9.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

XPC-6444

1 Cited Publications

Cat. No.: HY-128772

CAS No.: 2230144-21-3

Purity: 98.85%

Target:

Sodium Channel

Research Areas:

Neurological Disease

XPC-6444 is a highly potent, isoform-selective, and CNS-penetrant Na_V1.6 inhibitor (IC₅₀=41 nM for hNa_V1.6). XPC-6444 also displays potent block of Na_V1.2 (IC₅₀=125 nM). XPC-6444 shows anticonvulsant activity .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

1

STAD 2

1 Cited Publications

Cat. No.: HY-P2261

CAS No.: 1542100-77-5

Target:

PKA

Research Areas:

Infection

STAD 2 is a potent and selective disruptor of PKA-RII, with a K_d of 6.2 nM. STAD 2 disrupts interactions between PKA and AKAP in an isoform-selective manner. STAD 2 displays antimalarial activity through a PKA-independent mechanism .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

CNX-1351

Cat. No.: HY-16596

CAS No.: 1276105-89-5

Target:

PI3K

Research Areas:

Cancer

CNX-1351 is a potent and isoform-selective targeted covalent PI3Kα inhibitor with IC₅₀ of 6.8 nM.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

JBI-589

Cat. No.: HY-153450

CAS No.: 2308504-22-3

Purity: 99.75%

Target:

Protein Arginine Deiminase

Research Areas:

Cancer

JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research .

Compare

loading...